苦参碱与拉米夫定联合治疗活动性肝硬化的临床疗效观察

目的　探讨苦参碱和拉米夫定治疗活动性肝硬化的临床疗效。方法　随机选择 15 1例活动性肝硬化患者 ,治疗组 63例 ,苦参碱 2 0 0mg ,静脉滴注 ,qd ,8wk为 1疗程 ;拉米夫定 0 . 1,qd ,疗程 1年 ,产生应答者继续服用药物半年。各组在性别、年龄、病程及疾病轻重等方面皆具可比性。观察治疗前后肝功、肝纤维化指标及 1、3、6、12个月的HBV DNA变化。结果　苦参碱和拉米夫定治疗组与对照组比较肝功能、肝纤维化指标下降 ,HBV DNA的阴转率增加 ,经统计学处理有显著性差异 (P <0 . 0 5 )。结论　苦参碱和拉米夫定治疗活动性肝硬化有明显的临床疗效。是抗病毒、抗肝纤维化的有效药物。

The clinical therapeutic effect of matrine and lamivudine on the active cirrhosis

Objective To investigate the clinical therapeutic effect of matrine and lamivudine on the active hepatocirrhosis. Methods Sixty three patients with active hepatocirrhosis received matrine and lamivudine(matrine 200mg daily for 8 weeks, lamivudine 100 mg Daily for 1 year). The liver function, the values of serum liver fibrosis including hyaluronia acid (HA), laminin (LN), procollagen type III(PC III), procollagen type IV(IV C) before and after matrine and lamivudine administration were compared. HBV-DNA at 1, 3, 6, 12 months after matrine and lamivudine treatment were detected. Results The value of ALT, AST of treatment group was decreased comparing the control groups, the value of serum liver fibrosis markers were decreased after treatment. Differences between therapy group and control group were obvious (P<0. 01). The value of HBV-DNA was decreased in treatment comparing the control group. Conclusion Matrine and lamivudine showed an obvious effect on the treatment of active hepatocirrhosis.